

45. Schutte AE, Myburgh A, Olsen MH, Eugen-Olsen J, Schutte R. Exploring soluble urokinase plasminogen activator receptor and its relationship with arterial stiffness in a bi-ethnic population: the SAFrEIC-study. *Thromb Res* 2012;130:273-7.
46. Meijers B, Poesen R, Claes K, Dietrich R. Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. *Kidney Int* 2015;87:210-6.
47. Pawlak K, Pawlak D, Mysliwiec M. Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients. *Thromb Res* 2007;120:871-6.
48. Botha S, Fourie CM, Schutte R, Kruger A, Schutte AE. Associations of suPAR with lifestyle and cardiometabolic risk factors. *Eur J Clin Invest* 2014;44:619-26.
49. Intzilakis T, Hartmann G, Mouridsen MR, et al. Soluble urokinase plasminogen activator receptor, C-reactive protein and triglyceride are associated with heart rate variability in non-diabetic Danes. *Eur J Clin Invest* 2013;43:457-68.
50. Kjellman A, Akre O, Gustafsson O, et al. Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening. *J Intern Med* 2011;269:299-305.
51. Booth RA, Hill SA, Don-Wauchope A, et al. Performance of BNP and NT-proBNP for diagnosis of heart failure in primary care patients: a systematic review. *Heart Fail Rev* 2014;19:439-51.
52. Portelli MA, Siedlinski M, Stewart CE, et al. Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels. *FASEB J* 2014;28:923-34.
53. Zacho J, Tybjaerg-Hansen A, Jensen JS, et al. Genetically elevated C-reactive protein and ischemic vascular disease. *N Engl J Med* 2008;359:1897-908.

Erratum



In the article “2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation” by Verma et al., published in the October 2014 issue of the *Canadian Journal of Cardiology* (Can J Cardiol 2014;30:1114-30), the authors wish to correct unfortunate errors that crept into the text:

1. In affiliation “i”, the city should be listed as “Halifax.”
2. Reference 36a should be added for the “EMBRACE trial,” at the end of page 1118: Gladstone DJ, Spring M, Dorian P, et al; for the EMBRACE Investigators and Coordinators. Atrial fibrillation in patients with cryptogenic stroke. *N Engl J Med* 2014;370:2467-77.
3. On page 1121, the following text incorrectly appears twice in Recommendation 15: “followed by therapeutic OAC for at least 4 weeks after cardioversion.”
4. On page 1122, in paragraph regarding “BRUISE Control trial,” above Recommendation 16, the text in parentheses should read “CHADS₂ > 2,” not “CHADS₂ ≥ 2.”
5. Renal function measurements repeatedly stated as GFR in the paper should be presented as CrCl, and renal function units stated as “mL/min/1.73 m²” should simply be mL/min.

We deeply apologize for these errors.